Definium’s shares surge 55% after LSD-based depression pill delivers strong results

Definium Therapeutics reported that a single dose of its LSD-based experimental pill significantly reduced major depression symptoms in a late-stage trial, leading to a 55% surge in its shares to a four-year high. Patients on the drug recorded lower depression scale scores than those on placebo after six weeks.